News | May 29, 2024
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
EBITDA before special items falls 1.3 percent to € 4.41 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Sales reflect continued strong growth in oncology and vaccines
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Subscribe To Our Newsletter & Stay Updated
